Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 178 of 178 entries
View as:
Phase: N/A
Priority: Normal
Start: 09/30/05
End: 03/31/13
Due: 03/31/14
Phase: N/A
Priority: Normal
Start: 10/31/14
End: 05/03/21
Due: 05/03/22
Phase: N/A
Priority: Normal
Start: 08/31/00
End: 02/28/07
Due: 02/28/08
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma | NCT00193492 | SCRI Development Innovations, LLC | user2@example.com | None | 2005-09-30 | 2013-03-31 | 2014-03-31 | - | - | 2025-07-14 |
| Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer | NCT02125084 | SCRI Development Innovations, LLC | user2@example.com | None | 2014-10-31 | 2021-05-03 | 2022-05-03 | - | - | 2025-07-14 |
| Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma | NCT00193193 | SCRI Development Innovations, LLC | user2@example.com | None | 2000-08-31 | 2007-02-28 | 2008-02-28 | - | - | 2025-07-14 |